CANDIDEMIA

DEFINISI

Infeksi candida bisa terjadi pada hampir seluruh bagian tubuh manusia dan pada umumnya
berkembang pada mukosa tapi infeksi ini juga bisa berada pada aliran darah manusia, saat
candida berada pada aliran darah maka kondisi ini disebut Candidemia.1

ETIOLOGI

Candidemia disebabkan oleh bakteri yang disebut candida yang memiliki lebih dari 17
spesies namun 90% dari penyebab penyakit ini adalah Candida albicans, Candida glabrata,
Candida parapsilosis, candida trapicalis dan candida krusei.2

ETIOPATOGENIS

Candidemia paling sering terjadi di rumah sakit pada saat seminggu setelah dirawat di ICU
dan bisa juga disebabkan oleh terpasangnya cantral venous catheter (CPC), dialisis ginjal,
operaasi besar, sistem imunitas yang lemah, antibiotik spektrum luas, steroid intravena1

GAMBARAN KLINIS

Gambaran klinis dari infeksi candida bergantung pada tempat inffeksi tersebut namu pada
candidemia gambaran klinis yang mungkin dijumpai berupa:1

 Demam dan menggigil

 Ruam pada kulit
 Kelelahan secara umum
 Tekanan darah rendah
 Nyeri otot
 Perubahan pada mata atau adanya infeksi pada mata
 Sakit kepala dan defisit neurologis
 Sakit perit

Daftar pustaka

1. American Thoracic Society. 2012. Patient Information Series. Access at:

www.thoracic.org
2. Pfaller, M. A., Diekema, D. J., Procop, G. W. & Rinaldi, M. G. (2007). Multicenter
comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth
microdilution reference method for testing amphotericin B, flucytosine, and
voriconazole against Candida spp. J Clin Microbiol 45, 3522–3528.
 DAFTAR PUSTAKA

1. İnci M, Altay MA, Koç AN, Yula E, Evirgen Ö, Durmaz S, Demir G (2012) Investigating
virulence factors of clinical Candida isolates inrelation to atmospheric conditions and
genotype. Turk J Med Sci 42: 1476-1483.
2. Mohandas V, Ballal M (2011) Distribution of Candida species in different clinical samples and
their virulence: Biofilm formation, proteinase and phospholipase production: A study on
hospitalized patients in Southern India. J Glob Infect Dis 3: 4-8.
3. Gokce G, Cerikcioglu N, Yagcı A (2007) Acid proteinase, phospholipase and biofilm
production of Candida species isolated from blood cultures. Mycopathologia 164: 265-269.
4. Mohan das V, Ballal M (2008) Proteinase and phospholipase activity as virulence factors in
Candida species isolated from blood. Rev IberoamMicol 25: 208-210.
5. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP(1999) Nosocomial
bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 29:
239-244.
6. Pfaller MA, Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public
health problem. Clin Microbiol Rew 20: 133-163.
7. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S (1997) The epidemiology
of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 24:1122-
1128.
8. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD (1995) Antifungal susceptibility testing of
isolates from a randomized, multicenter trial of fluconazole versus amphotericin B for the
treatment of nonneutropenic patients with candidemia. Antimicrob Agents Chemother 39:
40-44.
9. Wingard JR (1995) Importance of Candida species other than C. albicans as pathogens in
oncology patients. Clin Infect Dis 20: 115-125.
10. Pfaller MA, Jones RN, Doern GV, Sader HS, Messer SA, Houston A, Coffman S, Hollis RJ (2000)
Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program
in North America and Latin America, 1997-1998. Antimicrob Agents Chemother 44: 747-751.
11. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME, Hajjehb RA (1999) Trends
in species distribution and susceptibility to fluconazole among blood stream isolates of
Candida species in the United States. Diagn Microbiol Infect Dis 33: 217-222.
12. Saghrouni F, Ben Abdeljelil J, Boukadida J, Ben Said M (2013) Molecular methods for strain
typing of Candida albicans: a review. J Appl Microbiol 114: 1559-1574.
13. Sardi JC, Duque C, Höfling JF, Gonçalves RB (2012) Genetic and phenotypic evaluation of
Candida albicans strains isolated from subgingival biofilm of diabetic patients with chronic
periodontitis. Med Mycol 50: 467-475.
14. Gultekin B, Eyigör M, Tiryaki Y, Kırdar S, Aydın N (2011) Investigation of antifungal
susceptibilities and some virulence factors of Candida strains isolated from blood cultures
and genotyping by RAPD-PCR. Mikrobiyol Bul 45: 306-317.
15. Akyol V, Cerikcioglu N (2010) Morphotyping, genotyping and investigation of some virulence
factors in different morphotypes of Candida parapsilosis clinical isolates. Mikrobiyol Bul 44:
605-617.
16. Kuzucu C, Durmaz R, Otlu B, Aktas E, Gulcan H, Cizmeci Z (2008) Species distribution,
antifungal susceptibility and clonal relatedness of Candidaisolates from patients in Mutlu
Sariguzel et al. – Genotypes and virulence factors of Candida spp. J Infect Dev Ctries 2015;
9(8):857-864. 864 neonatal and pediatric intensive care units at a medical center in Turkey.
New Microbiol 31: 401-408.
17. American Thoracic Society. 2012. Patient Information Series. Access at:
www.thoracic.org
18. Pfaller, M. A., Diekema, D. J., Procop, G. W. & Rinaldi, M. G. (2007). Multicenter
comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth
microdilution reference method for testing amphotericin B, flucytosine, and
voriconazole against Candida spp. J Clin Microbiol 45, 3522–3528.
19. White TJ, Burns T, Lee S, Taylor JW (1990) Amplications and direct sequencing of fungal
ribosomal RNA genes for phylogenetics. In Innis MA, Gelfand DH, Sninsky JJ, White TJ,
editors. PCR Protocols: A Guide to Methods and Applications, New York: Academic Press.
315-322.
20. Price MF, Wilkinson ID, Gentry LO (1982) Plate method for detection of phospholipase
activity in Candida albicans. Sabouraudia 20: 7-14.
21. Willis AM, Coulter WA, Fulton CR, Hayes JR, Bell PM, Lamey PJ (2001) The influence of
antifungal drugs on virulence properties of Candida albicansin patients with diabetes
mellitus. Oral Surg Oral Med Oral Pathol Oral RadiolEndod91: 317-321.
22. Staib F (1965) Serum-proteins as nitrogen source for yeastlike fungi. Sabouraudia 4: 187-193.
23. Toledo-Arana A, Valle J, Solano C, Arrizubieta MJ, Cucarella C, Lamata M, Amorena B, Leiva J,
Penades JR, Lasa I (2001) The enterococcal surface protein, Esp, is involved in Enterococcus
faecalis biofilm formation. Appl Environ Microbiol 67: 4538-4545.
24. Samaranayake LP, Raeside JM, MacFarlane TW (1984) Factors affecting the phospholipase
activity of Candida species in vitro. Sabouraudia 22: 201-207.
25. Slifkin M (2000) Tween 80 opacity test responses of various Candida species. J Clin Microbiol
38: 4626-4628.
26. Pfaller MA (1996) Nosocomial candidiasis: Emerging species, reservoirs and modes of
transmission. Clin Infect Dis 22: 89-94.
27. Vinitha M, Ballal M (2007) Biofilm as virulence marker in Candida isolated from blood. W J
Med Sci 2: 46-48.
28. Yücesoy M, Marol S (2003) Determination of esterase activity of Candida varieties.
Mikrobiyol Bul 37: 59-63.
29. Baillie GS, Douglas LJ (1999) Candida biofilm and their susceptibility to antifungal agents.
Methods Enzymol 310: 644-656.
30. Ozkan S, Kaynak F, Kalkancı A, Abbasoglu U, Kustimur S (2005) Slime production and
proteinase activity of Candida species isolated from blood samples and comparison of these
activities with minimum inhibitory concentration values of antifungal agents. Mem Inst
Oswaldo Cruz 100: 319-324.
31. Demirbilek M, Timurkaynak F, Can F, Azap O, Arsalan H (2007) Biofilm production and
antifungal susceptibility patterns of Candida species isolated from hospitalized patients.
Mikrobiyol Bul 41: 261-269.
32. Vinitha M, Ballal M (2009) Activity of proteinase, phospholipase and biofilm as virulence
markers in Candida species isolated from haematogenous samples. J Hosp Infect 73: 94-95.
33. Branchini ML, Pfaller MA, Rhine-Chalberg J, Frempong T, Isenberg HD (1994) Genotypic
variation and slime production among blood and catheter isolates of Candida parapsilosis. J
Clin Microbiol 32: 452-456.
34. Pfaller MA, Messer SA, Hollis RJ (1995) Variations in DNA subtype antifungal susceptibility
and slime production among clinical isolates of Candida parapsilosis. Diagn Microbiol Infect
Dis 21: 9-14.
35. Boccia S, Posteraro B, La Sorda M, Vento G, Matassa PG, Tempera A, Petrucci S, Fadda G
(2002) Genotypic analysis by 27 DNA fingerprinting of Candida albicans strains isolated
during an outbreak in a neonatal intensive care unit. Infect Control Hosp Epidemiol 23: 281-
284.
36. Marol S, Yucesoy M (2008) Molecular epidemiology of Candida species isolated from clinical
specimens of intensive care unit. Mycoses 51: 40-49.
37. Gagneur A, Sızun J, Vernotte E, De Parscau L, Quinio D, Le Flohıc AM, Baron R (2001) Low
rate of Candida parapsilosis-related colonization and infection in hospitalized preterm
infants: a one-year prospective study. J Hosp Infect 48: 193-197.
38. Shin JH, Shin DH, Song JW, Kee SJ, Suh SP, Ryang DH (2001) Electrophoretic karyotype
analysis of sequential Candida parapsilosis isolates from patients with persistent or
recurrent fungemia. J Clin Microbiol 39: 1258-1263.
39. Bendel CM (2003) Colonization and epithelial adhesion in the pathogenesis of neonatal
candidiasis. SeminPerinatol 27: 357- 364.
40. Hedderwick SA, Lyons MJ, Liu M, Vazquez JA, Kauffman CA (2000) Epidemiology of yeast
colonization in the intensive care unit. Eur J Clin Microbiol Infect Dis 19: 663- 670.
41. Barchiesi F, Caggiano G, Falconi DF, Montagna MT, Barbutı S, Scalise G (2004) Outbreak of
fungemia due to Candida parapsilosis in a pediatric oncology unit. Diagn Microbiol Infect Dis
49: 269-271.
42. Dou HT, Xu YC, Wang HZ, Li TS (2015) Molecular epidemiology of Cryptococcus neoformans
and Cryptococcus gattii in China between 2007 and 2013 using multilocus sequence typing
and the DiversiLab system. Eur J Clin Microbiol Infect Dis 34: 753-762.